Clinical Course of the Syndrome of Autoantibodies to the Insulin Receptor (Type B Insulin Resistance): A 28-Year Perspective
The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
Introduction The type B insulin resistance syndrome is a manifestation of autoantibodies to the insulin receptor. It is representative of a class of disease in which an autoantibody is produced against a cell surface receptor (9,79). Graves disease, caused by autoantibodies to the thyroid stimulating hormone receptor, and myasthenia gravis, caused by autoantibodies to the acetylcholine receptor at the myoneural junction, are typical of these diseases (30). Other rare syndromes include gonadal deficiencies and iron deficiencies (46,61). The exact prevalence of type B insulin resistance syndrome is not known; however, it is quite rare. There have been no population-based studies to answer the question of disease prevalence. Autoantibodies to the insulin receptor were first identified in middle-aged women with other autoimmune diseases (26,36). Subsequently, it was recognized that the disease also affects males and younger patients (4,15,24,53). The disease causes a spectrum of abnormalities in glucose homeostasis, ranging from extreme insulin resistance (30) to fasting hypoglycemia (30,69), and in some other cases a change from extreme insulin resistance to intractable hypoglycemia (1,67,69). In addition, the abnormalities in glucose homeostasis may remit in association with the disappearance of the antibody to the insulin receptor. While all these phenomena have been observed and reported over the years, little is known about the long-term prognosis of the patients. Furthermore, various treatment modalities have been employed to treat the syndrome without adequate appreciation of the disease course in the long run. In this paper we review the natural history of type B insulin resistance syndrome using clinical data from 24 patients followed for up to 28 years. Methods Patients and objective Twenty-four patients with the diagnosis of type B insulin resistance syndrome were admitted to the Clinical Center of the National Institutes of Health (NIH), Bethesda, Maryland, between January 1973 and December 2000. The data gathered on these patients were retrospectively evaluated to draw conclusions about the clinical outcomes. Criteria for inclusion Patients were required to have demonstrable autoantibodies against the insulin receptor in association with a clinical abnormality of glucose homeostasis, that is, hyperglycemia or hypoglycemia. Data collection Because of the wide geographic origins of these patients, it was not possible to follow each patient at the Clinical Center for the duration of time reported; therefore, we have supplemented our information by correspondence and telephone. Each patient underwent a detailed history and physical examination and in most cases they were followed for months or years at the Clinical Center. As retrospective information on each case was compiled, specific attention was given to delineate the onset of the syndrome, associated features, therapeutic interventions, outcome of therapy and metabolic responses (resolution of glucose abnormalities) over the course of follow-up, current status, and mortality. In addition, a similar approach was taken to derive complete follow-up information on cases reported in the literature wherever possible. Laboratory tests All patients underwent a battery of routine hematologic, immunologic, and biochemical tests on their initial examination, and on multiple subsequent time points. Most patients underwent a standard oral glucose tolerance test, and patients presenting with hypoglycemia underwent a diagnostic fast at least at the time of initial presentation. Each patient was proven to have an insulin receptor autoantibody by assays that measured either inhibition of insulin binding or blocking the biologic activity of insulin (30). A newer method detected antireceptor antibody by measuring immunoprecipitation of recombinant human insulin receptors. This method, developed in 1997, has improved specificity and sensitivity (Figure 1).Fig. 1: A newer method detected anti-insulin receptor antibody by measuring immunoprecipitation of recombinant human insulin receptors. Cos 7 cells were transfected with recombinant human insulin receptors using LipofectAMINE Plus according to manufacturer’s instructions (Life Technologies, Gaithersburg, MD). The cells were solubilized for 30 minutes on ice and insoluble debris removed by centrifugation (14,000 G for 20 minutes) at 4 °C. To test for the presence of the antireceptor antibody in the patients’ sera, 150 μL of extract was incubated with 2 μL of patient serum overnight at 4 °C. The antibody bound receptors were precipitated with peroxidase-affinity pure Fab′ 2 fragment goat antirabbit IgG −Fc fragment specific antibody (Jackson Immunological Research, West Grove, PA) and blotted with anti-insulin receptor β-subunit rabbit polyclonal antibody (C19) (Santa Cruz, CA). Nine samples were screened on the gel shown. Samples on Lane 1 and 8 are positive. Samples on lane 8 and 9 belong to the same patient at 2 d
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, rare patients with fasting hypoglycemia and appropriately suppressed C-peptide levels but inappropriately elevated insulin levels have an agonist antibody to the insulin receptor (70).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [70]
In the citing paper
“In that instance hypoglycemia is the result of the action of the antibody to stimulate insulin receptors; somewhat elevated insulin levels are thought to be the result of decreased clearance of insulin.”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [70]
In the citing paper
“In our experience, patients with extreme insulin resistance as a result of receptor mutations 17,18 or autoantibodies 19 do not have NASH-associated findings such as hypertriglyceridemia, hepatomegaly, or abnormal liver function tests.”
From Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy† (2005) · cites this paper as [19]
Citations
Cites
Durnin, J. V. G. A., & Womersley, J. (1974) · British Journal of Nutrition · doi:10.1079/bjn19740060 · Cited by 6,343
The Syndromes of Insulin Resistance and Acanthosis Nigricans: Insulin-Receptor Disorders in Man
Kahn, C. R., Flier, J. S., Bar, R. S., Archer, J. A., Gorden, P., Martin, M. M., & Roth, J. (1976) · New England Journal of Medicine · doi:10.1056/nejm197604012941401 · Cited by 1,106
Freychet, P., Roth, J., & Neville, D. M. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1833 · Cited by 498
Flier, J. S., Kahn, C. R., Roth, J., & Bar, R. S. (1975) · Science · doi:10.1126/science.170678 · Cited by 438
Direct demonstration that receptor crosslinking or aggregation is important in insulin action
Kahn, C. R., Baird, K. L., Jarrett, D. B., & Flier, J. S. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.9.4209 · Cited by 389
SOME VIRUS ISOLATIONS FROM COMMON COLDS
Hitchcock, G., & Tyrrell, D. A. J. (1960) · The Lancet · doi:10.1016/s0140-6736(60)90167-7 · Cited by 357
Taylor, S. I. (1992) · Diabetes · doi:10.2337/diab.41.11.1473 · Cited by 344
Self-citationFuller, N. J., Laskey, M. A., & Elia, M. (1992) · Clinical Physiology · doi:10.1111/j.1475-097x.1992.tb00831.x · Cited by 236
Shechter, Y., Maron, R., Elias, D., & Cohen, I. R. (1982) · Science · doi:10.1126/science.7041258 · Cited by 167
Hypoglycemia Associated with Antibodies to the Insulin Receptor
Taylor, S. I., Grunberger, G., Marcus-Samuels, B., Underhill, L. H., Dons, R. F., Ryan, J., Roddam, R. F., Rupe, C. E., & Gorden, P. (1982) · New England Journal of Medicine · doi:10.1056/nejm198212023072303 · Cited by 154
Self-citation
Research works printed but not linked: 9
- Auclair, 1999, J Clin Endocrinol Metab, 84, 3197
- Dozio, 1998, J Clin Endocrinol Metab, 83, 643
- Gill, 1994, J Reprod Med, 39, 126
- Jennette, 1982, Arch Pathol Lab Med, 106, 218
- Kramer, 1998, J Rheumatol, 25, 816
- O’Brien, 1994, J Clin Endocrinol Metab, 79, 290
- Sluss, 1992, J Clin Endocrinol Metab, 74, 1242
- Tardella, 1983, J Clin Lab Immunol, 12, 159
- Varga, 1990, J Rheumatol, 17, 1226
Cited by
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1410 · Cited by 1,277
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Genetic Syndromes of Severe Insulin Resistance
Semple, R. K., Savage, D. B., Cochran, E. K., Gorden, P., & O'Rahilly, S. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0020 · Cited by 358
Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis
Semple, R. K., Sleigh, A., Murgatroyd, P. R., Adams, C. A., Bluck, L., Jackson, S., Vottero, A., Kanabar, D., Charlton-Menys, V., Durrington, P., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37432 · Cited by 344
Metadata
- Authors
- ARIOGLU, E., ANDEWELT, A., DIABO, C., BELL, M., TAYLOR, S. I., & GORDEN, P.
- Affiliations
- National Institutes of Health (US)
- ORCID
- TAYLOR, SIMEON I.
- Venue
- Medicine
- Published
- 2002-03
- Volume
- 81
- Issue
- 2
- Pages
- 87-100
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2087454504
- Semantic Scholar
- 1e2e84bde977c42857f99e6ecf4001376d1b832a
- Cited by
- 223
- References
- 84
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 10 · 2023: 16 · 2022: 12 · 2021: 10 · 2020: 16 · 2019: 8 · 2018: 9 · 2017: 8 · 2016: 15 · 2015: 11 · 2014: 10 · 2013: 9 · 2012: 10
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
- Keywords
- type B insulin resistance syndrome, insulin receptor antibodies, insulin resistance, hypoglycemia, hyperglycemia, glucose homeostasis, long-term prognosis, natural history (disease), remission, treatment outcomes, autoimmune disease, clinical course, immunosuppressive therapy, Graves' disease, myasthenia gravis
- MeSH terms
- Acanthosis Nigricans, Adolescent, Adrenal Cortex Hormones, Adult, Aged, Autoimmune Diseases, Body Composition, Cause of Death, Child, Female, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Immunosuppressive Agents, Insulin Resistance, Male, Middle Aged, Plasmapheresis, Receptor, Insulin, Retrospective Studies, Syndrome, United States, Hyperandrogenism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Course of the Syndrome of Autoantibodies to the Insulin Receptor (Type B Insulin Resistance): A 28-Year Perspective. https://app.cochat.ai/papers/10.1097/00005792-200203000-00001
- The paper
- ARIOGLU, E., ANDEWELT, A., DIABO, C., BELL, M., TAYLOR, S. I., & GORDEN, P. (2002). Clinical Course of the Syndrome of Autoantibodies to the Insulin Receptor (Type B Insulin Resistance): A 28-Year Perspective. Medicine. https://doi.org/10.1097/00005792-200203000-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.